Citations

Clear

248 citation(s) found for "Bhatt, S".

Abstract 12577: Markers of Residual Risk in Type 2 Diabetes and Stable Ischemic Heart Disease: Insights From the BARI 2D Trial
Vlachos, Helen, Chaitman, Bernard, Frye, Robert L. , Everett, Brendan M. , Brooks, Maria M. , Bhatt, Deepak L.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 134 | Issue: suppl_1 | Pages: No page available

10.1161/circ.134.suppl_1.12577 Get It

Background: In spite of aggressive preventive therapy, patients with type 2 diabetes (T2D) and stable ischemic heart disease (SIHD) remain at high risk for major cardiovascular events and death. Understanding the pathophysiologic determinants of that residual risk could help identify effective preventive therapies. Methods and Results: In this Ancillary Study of the BARI 2D trial, we examined the predictive value of biomarkers from 6 distinct pathophysiologic pathways in 2285 men and women with T2D and SIHD who were followed for a median (IQR) of 5.0 (4.1-6.0) years. The endpoint for this Ancillary Study was a composite of myocardial infarction, stroke, heart failure, or all-cause mortality. The 5-year Kaplan-Meier event rate was 31%. The pathophysiologic processes evaluated included dysglycemia (HbA1c), dyslipidemia (LDL-C), myocardial strain (NT-proBNP), myocardial injury (high-sensitivity cardiac troponin T [hsTnT]), subclinical inflammation (high-sensitivity C-reactive protein [hsCRP]), and nephropathy (presence/absence of macroalbuminuria). In Cox proportional hazards models adjusted for baseline risk factors, angiographic severity of disease, and ejection fraction, each marker except LDL-C was a significant predictor of outcome (Figure) in this population with 74% baseline statin use. After mutual adjustment for all 6 markers and baseline risk factors, the hazard ratio (95% CI) per 1-SD of natural logarithm transformed concentration was largest for NT-proBNP [1.29 (1.17, 1.42)], followed by hsTnT [1.16 (1.07, 1.26)], HbA1c [1.12 (1.03, 1.21)], and hsCRP [1.11 (1.03, 1.20). Macroalbuminuria was not a significant predictor after adjustment for the other markers (Figure). Conclusions: In this high-risk population of patients with type 2 diabetes and stable ischemic heart disease, strategies to target myocardial strain, myocardial injury, and subclinical inflammation may lead to improvements in cardiovascular outcome.
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Buch, Maya H , Bhatt, Deepak L. , Charles‐Schoeman, Christina , Giles, Jon T. , Koch, Gary G., Ytterberg, Steven R. , Nagy, Edward, Jo, Hyejin, Connell, Carol A., Masri, Karim R. , Yndestad, Arne, Ytterberg, Steven, Masri, Karim Richard , Bhatt, Deepak L , Giles, Jon T , Mikuls, Ted R. , Kwok, Kenneth

Mayo Clinic

RMD Open | April 12, 2024 | Volume: 10 | Issue: 2 | Pages: e003912

10.1136/rmdopen-2023-003912 | PMID 38609322 Get It

Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral Rheumatoid Arthritis Trial (ORAL) Surveillance. Methods Patients with RA aged ≥50 years and with ≥1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. MACE (non-fatal myocardial infarction (MI), non-fatal stroke or CV death (MACE-3)) was extended by sequential addition of CV events (hospitalisation for unstable angina (MACE-4), coronary revascularisation (MACE-5), transient ischaemic attack (MACE-6), peripheral vascular disease (MACE-7)), heart failure (HF) hospitalisation (MACE-8) and venous thromboembolism (VTE; (MACE-8 plus VTE)). HRs (tofacitinib vs TNFi) were evaluated for MACE and individual components. Results HRs for MACE-4 to MACE-8 with combined and individual tofacitinib doses versus TNFi were similar. Risk of MACE-8 plus VTE appeared similar with tofacitinib 5 mg two times per day versus TNFi (HR 1.12 (0.82 to 1.52)), but higher with tofacitinib 10 mg two times per day versus TNFi (HR 1.38 (1.02 to 1.85)). Risk of MI was higher with tofacitinib versus TNFi, but difference in risk of other individual CV events was not suggested. Across extended MACE definitions, risk appeared higher with tofacitinib versus TNFi in those with atherosclerotic CV disease or age ≥65 years. Conclusion In ORAL Surveillance, risk of composite CV endpoints combining all ischaemic CV events and HF did not appear different with tofacitinib versus TNFi. The totality of CV risk was higher with tofacitinib 10 mg two times per day versus TNFi, driven by an increase in VTE. Trial registration number NCT02092467.
Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection and Ablation: A Large North American Multicenter Cohort
Vantanasiri, Kornpong , Joseph, Abel , Sachdeva, Karan , Goyal, Rohit , Garg, Nikita , Adoor, Dayyan , Kamboj, Amrit K. , Codipilly, Don C. , Leggett, Cadman L. , Wang, Kenneth K. , Harmsen, William S. , Hayat, Umar , Chak, Amitabh , Bhatt, Amit , Iyer, Prasad G. , Codipilly, Don Chamil , Leggett, Cadman L , Bhatt, Amit , Vantanasiri, Kornpong

Mayo Clinic

American Journal of Gastroenterology | April 8, 2024 | Volume: 119 | Issue: 9 | Pages: 1831-1840

10.14309/ajg.0000000000002798 | PMID 38587280 Get It

INTRODUCTION: Endoscopic eradication therapy (EET) combining endoscopic resection (ER) with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) followed by ablation is the standard of care for the treatment of dysplastic Barrett's esophagus (BE). We have previously shown comparable rates of complete remission of intestinal metaplasia (CRIM) with both approaches. However, data comparing recurrence after CRIM are lacking. We compared rates of recurrence after CRIM with both techniques in a multicenter cohort. METHODS: Patients undergoing EET achieving CRIM at 3 academic institutions were included. Demographic and clinical data were abstracted. Outcomes included rates and predictors of any BE and dysplastic BE recurrence in the 2 groups. Cox-proportional hazards models and inverse probability treatment weighting (IPTW) analysis were used for analysis. RESULTS: A total of 621 patients (514 EMR and 107 ESD) achieving CRIM were included in the recurrence analysis. The incidence of any BE (15.7, 5.7 per 100 patient-years) and dysplastic BE recurrence (7.3, 5.3 per 100 patient-years) were comparable in the EMR and ESD groups, respectively. On multivariable analyses, the chances of BE recurrence were not influenced by ER technique (hazard ratio 0.87; 95% confidence interval 0.51–1.49; P = 0.62), which was also confirmed by IPTW analysis (ESD vs EMR: hazard ratio 0.98; 95% confidence interval 0.56–1.73; P = 0.94). BE length, lesion size, and history of cigarette smoking were independent predictors of BE recurrence. DISCUSSION: Patients with BE dysplasia/neoplasia achieving CRIM, initially treated with EMR/ablation, had comparable recurrence rates to ESD/ablation. Randomized trials are needed to confirm these outcomes between the 2 ER techniques.
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients
Fleischmann, Roy , Mysler, Eduardo , Greenwald, Maria , Ytterberg, Steven R. , Koch, Gary G., Bhatt, Deepak L. , Wang, Cunshan, Mikuls, Ted R. , Chen, All‐shine, Connell, Carol A., Woolcott, John , Menon, Sujatha, Chen, Yan , Lee, Kristen , Fleischmann, Roy , Mikuls, Ted R , Szekanecz, Zoltán , Bhatt, Deepak L , Charles‐Schoeman, Christina

Mayo Clinic

Arthritis & Rheumatology | March 14, 2024 | Volume: 76 | Issue: 8 | Pages: 1218-1229

10.1002/art.42846 | PMID 38481002 Get It

Objective The ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance. Methods Patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor received tofacitinib 5 or 10 mg twice daily (BID) or TNFi. Post hoc, cumulative probabilities and incidence rates (patients with first events/100 patient‐years) by 6‐month intervals were estimated for adjudicated VTE, deep vein thrombosis, and PE. Cox regression models identified risk factors. Clinical Disease Activity Index leading up to the event was explored in patients with VTE. Results Cumulative probabilities for VTE and PE were higher with tofacitinib 10 mg BID, but not 5 mg BID, versus TNFi. Incidence rates were consistent across 6‐month intervals within treatments. Across treatments, risk factors for VTE included prior VTE, body mass index greater than or equal to 35 kg/m 2 , older age, and history of chronic lung disease. At the time of the event, most patients with VTE had active disease as defined by Clinical Disease Activity Index. Conclusion Incidences of VTE and PE were higher with tofacitinib (10 > 5 mg BID) versus TNFi and were generally consistent over time. Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, body mass index, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Litzow, Mark R. , Wingard, John R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J. , Üstün, Celalettin , Uy, Geoffrey L. , Vasu, Sumithra, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Mikesch, Jan‐Henrik , Onozawa, Masahiro , Thomson, Kirsty , Nagler, Arnon , Marcucci, Guido , Geller, Nancy L. , Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason E. , Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Wittsack, Heather, Mendizabal, Adam , Horowitz, Mary M. , Chen, Yi‐Bin , Investigators, on behalf of the BMT-CTN 1506/MORPHO Study, Agura, Ed, Altman, Jessica K. , Anagnostopoulos, Achiles, Aulitzky, Walter E. , Balderman, Sophia , Ballen, Karen K. , Béguin, Yves , Berkahn, Leanne, Bilmon, Ian , Briggs, Adrienne, Brunstein, Claudio G. , Byrne, Michael , Carrum, George, Černý, Jan , Ciceri, Fabio , Colorado, Mercedes , Cook, Rachel J. , Couriel, Daniel R. , Damon, Lloyd E. , Deol, Abhinav , Desbrosses, Yohan, Devine, Steve, Grazia, Carmela Di, Stasi, Antonio Di , Dias, Ajoy , Dorritie, Kathy, Essell, James , Eto, Tetsuya , Forcade, Édouard , Frankfurt, Olga, Fukuda, Takahiro , Fürst, Sabine , Goto, Tatsunori , Hall, Aric C. , Hatta, Shunsuke , Hicheri, Yosr , Horwitz, Mitchell E. , How, Jonathan, Howard, Dianna S. , Hsu, Wei‐Hsun , Huynh, Anne , Irvine, David, Ishikawa, Takayuki , Jamieson, Katarzyna , Wiktor-Jędrzejczak, W , Karakasis, Dimitrios, Kato, Jun , Kekre, Natasha , Khera, Nandita , Klein, A. , Kobbe, Guido , Kornblit, Brian, Lachance, Silvy , Levis, Mark J., Lin, Tung‐Liang , Litzow, Mark, Liu, Ta‐Chih, Martelli, Maurizio , Matsuoka, Ken‐ichi , McCarty, John M. , Mendez, Lourdes , Michelis, Fotios V. , Mikesch, Jan-Henrik, Mineishi, Shin , Moors, Ine , Motyckova, Gabriela, Mueller, Lutz Peter , Muffly, Lori, Nakamae, Hirohisa , Nathan, Sunita , Norkin, Maxim , Ogawa, Yoshiaki, Olesen, G., Onozawa, Masahiro, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Perl, Alexander E., Piątkowska‐Jakubas, Beata, Protheroe, Rachel, Ross, Kelly , Santarone, Stella , Sawa, Masashi , Schaar, Dale , Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart , Shah, Nilay , Shah, Nirav N. , Gil, Jorge Sierra, Sobecks, Ronald , Sprague, Kellie , Spyridonidis, Alexandros , Stelljes, Matthias , Stiff, Patrick J. , Tandra, Anand, Tholouli, Eleni , Thomas, Xavier , Tomlinson, Benjamin , Ustun, Celalettin, Uy, Geoffrey L., Ferreiras, David Valcarcel, Wagner, Eva , Watson, Anne-Marie, Wolschke, Christine, Yamauchi, Takuji , Yeh, Su‐Peng , Logan, Brent , Litzow, Mark R. , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Solh, Melham M , Mishra, Asmita , Muffly, Lori , Kim, Hee-Je , Najima, Yuho , Onozawa, Masahiro , Nagler, Arnon , Wei, Andrew H , Geller, Nancy , Hill, Jason , Gill, Stanley C , King, Denise , Devine, Steven , Horowitz, Mary , Chen, Yi-Bin , Hamadani, Mehdi , Ueda, Masumi , Waller, Edmund K. , Wei, Andrew H. , Devine, Steven M. , Investigators, on behalf of the BMT-CTN 1506/MORPHO Study, Anagnostopoulos, Achiles, Anand, Sarah , Artz, Andrew , Becker, Michael W. , Berneman, Zwi Nisan , Bhatt, Vijaya Raj , Bonifazi, Francesca , Bruno, Benedetto , Byrne, Jenny , Cabrero, Mónica , Cairoli, Roberto , Cheong, June‐Won , Colorado, Mercedes , Craddock, Charles , Grazia, Carmela Di, Farag, Sherif Shafik , Fujiwara, Shin‐ichiro , Fukushima, Kentaro , Hou, Hsin‐An , Jethava, Yogesh S. , Jiménez, Antonio , Jung, Chul Won , Kanda, Junya , Klein, Andreas, Kota, Vamsi , Leber, Brian F. , Lee, Catherine J , Lee, Je‐Hwan , Levis, Mark J., Litzow, Mark, Martínez, Carmen , Mikesch, Jan-Henrik, Mohty, Mohamad , Mueller, Lutz, Muffly, Lori, Nakano, Nobuaki , Nicholson, Emma , Oluwole, Olalekan O. , Onozawa, Masahiro, Pantin, Jeremy , Perl, Alexander E., Poiré, Xavier , Rambaldi, Alessandro , Ritchie, David , Rubio, Marie‐Thérèse , Sanz, Jaime , Shore, Tsiporah B. , Socié, Gèrard , Stuart, Robert K. , Tanaka, Masatsugu , Tiribelli, Mario , Tsirigotis, Panagiotis D. , Tzachanis, Dimitrios , Uchida, Naoyuki , Ustun, Celalettin, Uy, Geoffrey L., Ferreiras, David Valcarcel, Weisdorf, Daniel J. , Wróbel, Tomasz , Yakoub‐Agha, Ibrahim , Yared, Jean A. , Yoon, Sung‐Soo , Yoshihara, Satoshi

Mayo Clinic

Journal of Clinical Oncology | March 12, 2024 | Volume: 42 | Issue: 15 | Pages: 1766-1775

10.1200/jco.23.02474 | PMID 38471061 Get It

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202 ) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P = .575). CONCLUSION Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.
Imaging of the Posttreatment Head and Neck: Expected Findings and Potential Complications
Brahmbhatt, Sneh , Overfield, Cameron J. , Rhyner, Patricia A., Bhatt, Alok A. , Hudgins, P.A. , Hudgins, Patricia A , Bhatt, Alok A

Mayo Clinic

Radiology: Imaging Cancer | January 26, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1148/rycan.230155 | PMID 38276904 Get It

Submucosal Epstein-Barr Virus Positive Polymorphic B-cell Lymphoproliferative Disorder of the Larynx: A Case Report
Mumtaz, Sehreen , Candelo, Estephanía , Krishna, Murli , Jiang, Liuyan , Bhatt, Alok A. , Bridges, Margaret, Cardona-Cardona, Andrés Felipe , Rutt, Amy L. , Berianu, Florentina , Butendieck, Ronald R., Cardona, Andres , Rutt, Amy L. , Gomez, Estephania Candelo , Bhatt, Alok A , Mumtaz, Sehreen , Bridges, Margaret

Mayo Clinic

Ear, Nose & Throat Journal | January 24, 2024 | Volume: 105 | Issue: 8 | Pages: No page available

10.1177/01455613231226017 | PMID 38264837 Get It

Epstein-Barr virus (EBV) belongs to the group of human herpes virus and can cause clinical and subclinical infections. Although EBV-related disease presentations are similar, they can lead to oncogenic transformation with various clinical manifestations. A thorough workup with morphology, immunohistochemistry, and molecular studies is crucial for the diagnosis of EBV-positive polymorphic B-cell lymphoproliferative disorder, not otherwise specified (NOS), which is a new entity introduced by International Consensus Classification in 2022. We describe an interesting presentation of EBV-positive polymorphic B-cell lymphoproliferative disorder with laryngeal involvement to bring awareness to this entity and we would like to address the need for more accessible treatment options.
Guiding principles for the conduct of the Violence Study of Healthcare Workers and System (ViSHWaS): Insights from a global survey
Amal, Tanya , Bhatt, Gaurang , Faisal, Umme Habiba , Rais, Mohammed Amir , Najam, Nadia , Banga, Akshat , Khalid, Aisha , Surani, Salim , Nawaz, Faisal A. , Kashyap, Rahul

Mayo Clinic

Journal of Global Health | January 11, 2024 | Volume: 14 | Issue: No issue available | Pages: No page available

10.7189/jogh.14.04008 | PMID 38206325 Get It

Abstract 12855: Early vs. Late Transcatheter Aortic Valve Replacement in Acute Heart Failure Hospitalizations: National Inpatient Sample (2015-2020)
Khalouf, Amani, Mohamed, Mohamed Salah , Kashou, Anthony H. , Depta, Jeremiah P. , Hashem, Anas , Ismayl, Mahmoud , Rai, Devesh , Depta, Jeremiah P , Balla, Sudarshan , Sulaiman, Samian , Bhatt, Deepak L.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.12855 Get It

Introduction: Data on clinical outcomes of early transcatheter aortic valve replacement (TAVR) (<48 hours) compared to late (≥48 hours) TAVR in patients hospitalized with acute heart failure (AHF) and aortic stenosis (AS) remains limited. We aim to evaluate the differences between early vs. late TAVR regarding major clinical outcomes using a real-world US database. Hypothesis: There is no differences in the clinical outcomes based on the timing of TAVR procedural intervention in patients with acute heart failure. Methods: We used the National Inpatient Sample database by utilizing ICD-10 codes to identify all hospitalizations with a diagnosis of AHF and TAVR (2015-2020). The associations between the time of TAVR and outcomes were examined using multivariable logistic regression. Propensity-score matched (PSM) analysis was utilized to determine the adjusted odds ratio (aOR) of major clinical outcomes. Results: A total of 25,285 weighted hospitalizations of AHF were identified, of which 6,855 patients (27.1%) underwent early TAVR and 18,430 (72.9%) had late TAVR. Compared with early TAVR, Late TAVR was associated with less need for mechanical circulatory support (MCS) (aOR 0.97 [0.96-0.98], p<0.01) and acute hypoxic respiratory failure (aOR 0.99 [0.98-0.99], p<0.01), but higher odds of developing septic shock (aOR 2.06 [1.52-2.80], p <0.01). However, there was no significant difference between both procedures regarding in-hospital mortality (aOR 1.01 [1.00-1.02], p=0.14), cardiac arrest (aOR 0.99 [0.98-1.00], p=0.21), and stroke (aOR 1.01 [1.00-1.02], p=0.18). Conclusions: Most patients with AHF and AS undergo TAVR after 48 hours of their presentation. After PSM, there was no difference in inpatient mortality, cardiac arrest, and stroke between both procedures. Late TAVR was associated with lower odds for MCS and acute hypoxic respiratory failure. The optimal timing of TAVR in patients with AHF and AS needs further study.
An Interdisciplinary Intervention to Improve Time to Systemic Thrombolysis for Inpatient Acute Ischemic Strokes (5513)
Vanderhye, Vanesa, Bhatt, Shubhang K. , Dawit, Sara, Sands, Kara, Shiue, Harn , Pines, Andrew R. , Das, Devika

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.5513 Get It